Sergio Quezada

Company: Achilles Therapeutics

Job title: Chief Scientific Officer

Seminars:

Targeting Clonal Neoantigens with Precision T-Cell Therapies: Key Mechanistic Insights From cNeT Clinical Trials 11:00 am

Unique translational science platform enables us to track the active component of TIL (clonal neoantigen reactive T-cell) in patients and determine key mechanisms underpinning in vivo activity  Key insights to date include:  Impact of host conditioning in T-cell persistence and engraftment  Critical role of evasion mechanisms (such as HLA loss) in resistance to T-cell based therapiesRead more

day: Conference Day One - Track B - AM

Overcoming Neoantigen Screening Bottlenecks & Empowering Neoantigen Predictions for Expansion of Neoantigen Reactive TILs 1:05 pm

Many TIL developers face bottlenecks in screening for neoantigens and predicting immunogenicity and selectivity potential of discovered neoantigens, which exasperates manufacturing timelines. This workshop discusses solutions and current advancements to expedite processes, crucial for advancing TIL therapy development amidst burgeoning demand. Join this workshop to: Discuss the challenge of intratumor heterogeneity and tools for targeting…Read more

day: Pre-Conference Workshop Day